Beam Therapeutics Inc is trading 4.3% down at $31.53 on profit-taking following a sharp multi-day rally that pushed shares higher in late May.
- The move appears driven by normal volatility in the high-beta biotech name, with no new company-specific news or fresh analyst calls reported this morning.
- Broader indices are trading roughly flat, suggesting a consolidation phase after recent gains rather than a shift in fundamentals.